Medición de la respuesta a la inducción y mortalidad en 414 pacientes con Nefritis Lúpica en la región Caribe Colombiana
| datacite.rights | http://purl.org/coar/access_right/c_16ec | eng |
| dc.contributor.advisor | Guido Musso, Carlos | |
| dc.contributor.advisor | Aroca Martínez, Gustavo | |
| dc.contributor.advisor | González Torres, Henry J. | |
| dc.contributor.author | Peña Vargas, William Arturo | |
| dc.date.accessioned | 2021-02-01T16:54:50Z | |
| dc.date.available | 2021-02-01T16:54:50Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Objetivo: Evaluar la respuesta al tratamiento de inducción con dos esquemas de tratamiento uno con Mofetil Micofenolato (MMF) y otro con Ciclofosfamida (CFM) y la mortalidad en una serie de casos con NL en la región del Caribe colombiano. Método: Se realizó un estudio analítico con 414 pacientes con diagnóstico de NL clases III, IV y V confirmado por biopsia y tratados entre los años 2008-2020. Se evaluó la disminución de la Creatinina Serica (CrSr) y Proteinuria en 24 hrs (Prot24hrs), respuesta a tratamiento de inducción a la remisión (parcial o completa), así como la mortalidad y sus causas en los dos esquemas de tratamiento. Resultados: Se evaluaron 414 pacientes, de los cuales el 87% eran mujeres. La edad promedio fue de 37±13años. 324 fueron tratados con MMF y 90 CFM. La clase histológica predominante fue la clase IV (668.2%). La prot24hrs mostró una disminución en ambos esquemas, la Clase IV tratada con MMF mostró una disminución significativa (p: 0.0019). La CFM disminuyó significativamente la CrSr (p: 0.0025), especialmente en las Clases III (p: 0.0038) y IV (p: 0.0012); el MMF no disminuyó significativamente para este parámetro a excepción de la Clase V (0.0046). No hubo diferencias significativas en cuanto a la respuesta (remisión parcial o completa) entre esquemas, ni en la mortalidad o sus causas (p: 0.4215). Conclusiones: Ambos esquemas pueden utilizarse para la inducción en los pacientes con NL, tienen perfiles de efectividad y seguridad similares. La alta mortalidad por causas infecciosas indica la necesidad de realizar un mayor control sobre los pacientes y en la educación para la prevención de esta causa. | spa |
| dc.description.abstract | Objective: To evaluate the response to induction treatment with two treatment regimens, one with Mycophenolate Mofetil (MMF) and the other with Cyclophosphamide (CFM) and mortality in a series of cases with LN in the Colombian Caribbean region. Method: An analytical study was carried out with 414 patients with a diagnosis of LN classes III, IV and V confirmed by biopsy and treated between the years 2008-2020. The decrease in Serum Creatinine (CrSr) and Proteinuria in 24 hrs (Prot24hrs), response to remission induction treatment (partial or complete), as well as mortality and its causes in the two treatment schedules were evaluated. Results: 414 patients were evaluated, of which 87% were women. The mean age was 37 ± 13 years. 324 were treated with MMF and 90 CFM. The predominant histological class was class IV (668.2%). Prot24hrs showed a decrease in both regimens, Class IV treated with MMF showed a significant decrease (p: 0.0019). The CFM significantly decreased the CrSr (p: 0.0025), especially in Classes III (p: 0.0038) and IV (p: 0.0012); the MMF did not decrease significantly for this parameter except for Class V (0.0046). There were no significant differences in response (partial or complete remission) between regimens, nor in mortality or its causes (p: 0.4215). Conclusions: Both schemes can be used for induction in patients with LN, they have similar effectiveness and safety profiles. The high mortality from infectious causes indicates the need for greater control over patients and in education for the prevention of this cause. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.doi | http://doi.org/10.5281/zenodo.4676164 | |
| dc.identifier.issn | 26107988 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/7045 | |
| dc.identifier.url | http://www.revistaavft.com/images/revistas/2021/avft_1_2021/17_medicion_respuesta.pdf | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | AVFT Archivos Venezolanos de Farmacología y Terapéutica | spa |
| dc.source | Vol. 40 N° 1, (2021) | |
| dc.subject | Nefritis lúpica | spa |
| dc.subject | Inducción | spa |
| dc.subject | Biopsia renal | spa |
| dc.subject | Micofenolato | spa |
| dc.subject | Ciclofosfamida | spa |
| dc.subject | Mortalidad | spa |
| dc.subject | Lupus nephritis | eng |
| dc.subject | Induction | eng |
| dc.subject | Renal biopsy | eng |
| dc.subject | Mycophenolate | eng |
| dc.subject | Cyclophosphamide | eng |
| dc.subject | Mortality | eng |
| dc.title | Medición de la respuesta a la inducción y mortalidad en 414 pacientes con Nefritis Lúpica en la región Caribe Colombiana | spa |
| dc.title.translated | Measurement of the response to induction and mortality in 414 patients with Lupus Nephritis in the Colombian Caribbean region | eng |
| dc.type.driver | info:eu-repo/semantics/other | eng |
| dc.type.spa | Otros | spa |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. 2014. | eng |
| dcterms.references | Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA. Systemic lupus erythematosus: A review of the disease and treatment options. Consult Pharm. 2013;28(2):110-121. doi:10.4140/TCP.n.2013.110 | eng |
| dcterms.references | Zubair A, Frieri M. Lupus nephritis: Review of the LITERATURE. Curr Allergy Asthma Rep. 2013;13(6):580-586. doi:10.1007/s11882-013-0394-4 | eng |
| dcterms.references | Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329-341. doi:10.1038/nrneph.2015.33 | eng |
| dcterms.references | Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. doi:10.1002/acr.21664 | eng |
| dcterms.references | Jr GM. Systemic lupus erythematosus in three ethnic groups . XII . Risk. 2014;(September 2001):152-160. | eng |
| dcterms.references | Aroca-Martínez G. Propuesta de Un Modelo de Gestion de Salud de La Nefritis Lupica.; 2017. | spa |
| dcterms.references | Cervera R, Khamashta M a, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299-308. doi:10.1097/01.md.0000091181.93122.55 | eng |
| dcterms.references | Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. doi:10.2215/CJN.05780616 | eng |
| dcterms.references | Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016;31(6):904-913. doi:10.1093/ndt/gfv102 | eng |
| dcterms.references | Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: An analysis of predictive measures. J Rheumatol. 2012;39(1):79-85. doi:10.3899/jrheum.110532 | eng |
| dcterms.references | Dall’Era M. Treatment of lupus nephritis. Curr Opin Rheumatol. 2017;29(3):241-247. doi:10.1097/bor.0000000000000381 | eng |
| dcterms.references | Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of lowdose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. doi:10.1002/art.10461 | eng |
| dcterms.references | Aroca-Martínez G, Depine S, Consuegra-Machado JR, González-Torres HJ, Árquez-Mendoza M, Estrada-García E. Development and use of an application programming interface modified from GoogleMaps© for the georeferencing of patients with glomerular disease. Nefrol publicación Of la Soc Española Nefrol. 2015;35(1):118-120. doi:10.3265/Nefrologia.pre2014.Oct.12736 | eng |
| dcterms.references | Arnaud L, Fagot J-P, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. Autoimmun Rev. 2014;13(11):1082-1089. doi:10.1016/j.autrev.2014.08.034 | eng |
| dcterms.references | Yacoub Wasef SZ. Gender differences in systemic lupus erythematosus. Gend Med. 2004;1(1):12-17. doi:10.1016/s1550-8579(04)80006-8 | eng |
| dcterms.references | Ostensen M. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann N Y Acad Sci. 1999;876:131-143; discussion 144. doi:10.1111/j.1749-6632.1999.tb07630.x | eng |
| dcterms.references | Cutolo M, Sulli A, Villaggio B, Seriolo B, Accardo S. Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 1998;57(10):573-577. doi:10.1136/ard.57.10.573 | eng |
| dcterms.references | Riveros Frutos A, Casas I, Rúa-Figueroa I, et al. Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort. Lupus. 2017;26(7):698-706. doi:10.1177/0961203316673728 | eng |
| dcterms.references | Rúa-Figueroa Í, Richi P, López-Longo FJ, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore). 2015;94(1):e267. doi:10.1097/MD.0000000000000267 | eng |
| dcterms.references | Torrente-Segarra V, Salman Monte TC, Rúa-Figueroa I, et al. Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Clin Exp Rheumatol. 35(6):1047-1055. http://www.ncbi.nlm.nih.gov/pubmed/28628467. | eng |
| dcterms.references | de Carvalho JF, do Nascimento AP, Testagrossa LA, Barros RT, Bonfá E. Male gender results in more severe lupus nephritis. Rheumatol Int. 2010;30(10):1311-1315. doi:10.1007/s00296-009-1151-9 | eng |
| dcterms.references | Ramírez Sepúlveda JI, Bolin K, Mofors J, et al. Sex differences in clinical presentation of systemic lupus erythematosus. Biol Sex Differ. 2019;10(1):60. doi:10.1186/s13293-019-0274-2 | eng |
| dcterms.references | Tannor EK, Yeboah-Mensah K. Biopsy proven lupus nephritis in a black male patient in West Africa with systemic lupus erythematosus: case report. Pan Afr Med J. 2018;31:198. doi:10.11604/pamj.2018.31.198.14326 | eng |
| dcterms.references | Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol. 2011;75(3):233-241. doi:10.5414/cnp75233 | eng |
| dcterms.references | Anaya J-M, Cañas C, Mantilla RD, et al. Lupus nephritis in Colombians: contrasts and comparisons with other populations. Clin Rev Allergy Immunol. 2011;40(3):199-207. doi:10.1007/s12016-010-8249-4 | eng |
| dcterms.references | Kamitaki N, Sekar A, Handsaker RE, et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature. 2020;582(7813):577- 581. doi:10.1038/s41586-020-2277-x | eng |
| dcterms.references | Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. doi:10.1016/j.kint.2017.11.023 | eng |
| dcterms.references | Azoicăi T, Belibou IM, Lozneanu L, Giuşcă SE, Cojocaru E, Căruntu ID. Large variability of the activity and chronicity indexes within and between histological classes of lupus nephritis. Rom J Morphol Embryol. 2017;58(1):73-78. http://www.ncbi.nlm.nih.gov/pubmed/28523301. | eng |
| dcterms.references | Haladyj E, Mejía JC, Cervera R. Is the renal biopsy still necessary in lupus nephropathy? Rev Colomb Reumatol. 2016;23(2):69-72. doi:10.1016/j.rcreu.2016.04.001 | eng |
| dcterms.references | Bao H, Liu Z-H, Xie H-L, Hu W-X, Zhang H-T, Li L-S. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001-2010. doi:10.1681/ASN.2007121272 | eng |
| dcterms.references | Gul H, Mushtaq MS, Salim B, Samreen S, Nasim A, Khan M. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy. J Ayub Med Coll Abbottabad. 2020;32(4):454-458. http://www.ncbi.nlm.nih.gov/pubmed/33225643. | eng |
| dcterms.references | Rathi M, Goyal A, Jaryal A, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016;89(1):235-242. doi:10.1038/ki.2015.318 | eng |
| dcterms.references | Mendonca S, Gupta D, Ali S, Gupta P. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience. Saudi J Kidney Dis Transplant. 2017;28(5):1069- 1077. doi:10.4103/1319-2442.215147 | eng |
| dcterms.references | Jiang Y-P, Zhao X-X, Chen R-R, Xu Z-H, Wen C-P, Yu J. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and metaanalysis. Medicine (Baltimore). 2020;99(38):e22328. doi:10.1097/MD.0000000000022328 | eng |
| dcterms.references | Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22(7):1933-1942. doi:10.1093/ndt/gfm066 | eng |
| dcterms.references | Lee YH, Woo J-H, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19(6):703-710. doi:10.1177/0961203309357763 | eng |
| dcterms.references | Dai C, Deng Y, Quinlan A, Gaskin F, Tsao BP, Fu SM. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014;31:87-96. doi:10.1016/j.coi.2014.10.004 | eng |
| dcterms.references | Mageed RA, Prud’homme GJ. Immunopathology and the gene therapy of lupus. Gene Ther. 2003;10(10):861-874. doi:10.1038/sj.gt.3302016 | eng |
| dcterms.references | Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial. BMC Nephrol. 2018;19(1):175. doi:10.1186/s12882-018-0973-7 | eng |
| dcterms.references | Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89(4):227-235. doi:10.1097/MD.0b013e3181e93d00 | eng |
| dcterms.references | Hogan J, Schwenk MH, Radhakrishnan J. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int. 2012;82(12):1256-1260. doi:10.1038/ki.2012.203 | eng |
| dcterms.references | Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev. 2019;18(5):510-518. doi:10.1016/j.autrev.2019.03.004 | eng |
| dcterms.references | Liberman AC, Druker J, Refojo D, Arzt E. [Molecular mechanisms of action of some immunosuppressive drugs]. Medicina (B Aires). 2008;68(6):455-464. http://www.ncbi.nlm.nih.gov/pubmed/19147430. | eng |
| dcterms.references | Herrmann DB, Bicker U. Drugs in autoimmune diseases. Klin Wochenschr. 1990;68 Suppl 2:15-25. http://www.ncbi.nlm.nih.gov/pubmed/2198387. | eng |
| dcterms.references | Montiel D, Cacace P. Mortality and causes of death in patients with systemic lupus erythematosus. Rev Paraguaya Reumatol. 2019;5(2):51-57. doi:10.18004/rpr/2019.05.02.51-57 | eng |
| dcterms.references | Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. June 2018. doi:10.1002/14651858.CD002922.pub4 | eng |
| dcterms.references | Ramirez-Sandoval JC, Chavez-Chavez H, Wagner M, Vega-Vega O, Morales-Buenrostro LE, Correa-Rotter R. Long-term survival of kidney grafts in lupus nephritis: a Mexican cohort. Lupus. 2018;27(8):1303-1311. doi:10.1177/0961203318770527 | eng |
| dcterms.references | Ali OM, Sayed AA, Mohammed WS, Mohammed RR. Cardiovascular System Affection and Its Relation to First-Year Mortality in Patients Initiating Maintenance Hemodialysis. Int J Gen Med. 2020;13:379-385. doi:10.2147/IJGM.S242549 | eng |
| dcterms.references | Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. 2014. | eng |
| dcterms.references | Gurevitz SL, Snyder JA, Wessel EK, et al. Systemic lupus erythematosus: A review of the disease and treatment options. Consult Pharm 2013;28:110–21. doi:10.4140/TCP.n.2013.110 | eng |
| dcterms.references | Zubair A, Frieri M. Lupus nephritis: Review of the LITERATURE. Curr Allergy Asthma Rep 2013;13:580–6. doi:10.1007/s11882-013-0394-4 | eng |
| dcterms.references | Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015;11:329–41. doi:10.1038/nrneph.2015.33 | eng |
| dcterms.references | Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797–808. doi:10.1002/acr.21664 | eng |
| dcterms.references | Jr GM. Systemic lupus erythematosus in three ethnic groups . XII . Risk. 2014;:152–60. | eng |
| dcterms.references | Aroca-Martínez G. Propuesta de un modelo de gestion de salud de la nefritis lupica. 2017. | spa |
| dcterms.references | Cervera R, Khamashta M a, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299–308. doi:10.1097/01.md.0000091181.93122.55 | eng |
| dcterms.references | Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017;12:825–35. doi:10.2215/CJN.05780616 | eng |
| dcterms.references | Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant 2016;31:904–13. doi:10.1093/ndt/gfv102 | eng |
| dcterms.references | Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: An analysis of predictive measures. J Rheumatol 2012;39:79–85. doi:10.3899/jrheum.110532 | eng |
| dcterms.references | Dall’Era M. Treatment of lupus nephritis. Curr Opin Rheumatol 2017;29:241– 7. doi:10.1097/bor.0000000000000381 | eng |
| dcterms.references | Viana De Queiroz M. Lupus Eritematoso Sistemico. Acta Med Port 1994;7:343–8. | spa |
| dcterms.references | pe Corona-Sanchez EG. Lupus eritematoso sistémico: implicaciones de la inmunidad innata. El Resid 2015;10:4–11. | spa |
| dcterms.references | González V, González J. Lupus Eritematoso Sistémico (LES). Presentación de un caso. Systemic Lupus Erythematosus. Case presentation. 2017;4:75– 93. | spa |
| dcterms.references | Xu R, Li Q, Liu R, et al. Association Analysis of the MHC in Lupus Nephritis. J Am Soc Nephrol 2017;28:3383–94. doi:10.1681/ASN.2016121331 | eng |
| dcterms.references | Sociedad Mexicana de Alergia e Inmunología. RD, Carsolio-Trujano M, Herrera-Sánchez DA, et al. Revista alergia Mexico : organo oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C. Rev Alerg México 1993;62:265–70. | spa |
| dcterms.references | Zandman-Goddard G, Solomon M, Rosman Z, et al. Environment and lupusrelated diseases. Lupus 2012;21:241–50. doi:10.1177/0961203311426568 | eng |
| dcterms.references | Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1400–12. doi:10.1002/art.40930 | eng |
| dcterms.references | Coronado Alvarado CD, Gámez Saiz IL, Sotelo Cruz N. Características clínicas y comorbilidades de pacientes con lupus eritematoso sistémico en niños y adultos. Acta Pediátrica México 2018;1:1. doi:10.18233/apm1no1pp1- 121535 | spa |
| dcterms.references | Galindo M, Molina RA, Álvarez JLP. Lupus eritematoso sistémico (I). Etiopatogenia. Manifestaciones clínicas. Historia natural. Pruebas diagnósticas. Diagnóstico diferencial. Med - Programa Form Médica Contin Acreditado 2017;12:1429–39. doi:10.1016/j.med.2017.01.001 | spa |
| dcterms.references | Medlin JL, Hansen KE, Fitz SR, et al. A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. Semin Arthritis Rheum 2016;45:691–7. doi:10.1016/j.semarthrit.2016.01.004 | eng |
| dcterms.references | Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol 2016;17:135– 46. doi:10.1007/s40257-016-0173-9 | eng |
| dcterms.references | Kado R. Systemic Lupus Erythematosus for Primary Care. Prim Care Clin Off Pract 2018;45:257–70. doi:10.1016/j.pop.2018.02.011 | eng |
| dcterms.references | Nutan F, Ortega-Loayza AG. Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options. J Investig Dermatology Symp Proc 2017;18:S64–8. doi:10.1016/j.jisp.2017.02.001 | eng |
| dcterms.references | Ceccarelli F, Perricone C, Cipriano E, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. Semin Arthritis Rheum 2017;47:53–64. doi:10.1016/j.semarthrit.2017.03.022 | eng |
| dcterms.references | Kolasinski SL, Chi AS, Lopez-Garib AJ. Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis. Rheum Dis Clin North Am 2016;42:711–32. doi:10.1016/j.rdc.2016.07.007 | eng |
| dcterms.references | Fava A, Petri M. Systemic lupus erythematosus : Diagnosis and clinical management. J Autoimmun 2019;96:1–13. doi:10.1016/j.jaut.2018.11.001 | eng |
| dcterms.references | Acosta I, Avila G, Acosta M, et al. Manifestaciones clínicas y laboratoriales en el Lupus eritematoso sistemico- LES. 2016;14. | spa |
| dcterms.references | Alonso M. Lupus eritematoso sistémico. Epidemiología y presentación clínica en el noroeste de España. 2017. | spa |
| dcterms.references | Ghahramani M, Nudy M, Ruzieh M. LUPUS IN THE HEART. J Am Coll Cardiol 2019;73:2617. doi:10.1016/S0735-1097(19)33223-1 | eng |
| dcterms.references | Miner JJ, Kim AHJ. Cardiac Manifestations of Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2014;40:51–60. doi:10.1016/j.rdc.2013.10.003 | eng |
| dcterms.references | Sunjaya DB, Koster MJ, Osborn TG. 61-Year-Old Woman With Systemic Lupus Erythematosus and Chest Pain. Mayo Clin Proc 2017;92:153–8. doi:10.1016/j.mayocp.2016.04.034 | eng |
| dcterms.references | Tejeda-Maldonado J, Quintanilla-González L, Galindo-Uribe J, et al. Cirugía cardiaca en pacientes con lupus eritematoso sistémico: características clínicas y desenlaces. Reumatol Clínica 2018;14:269–77. doi:10.1016/j.reuma.2017.01.012 | spa |
| dcterms.references | Samura T, Toda K, Yoshioka D, et al. Libman-Sacks Endocarditis Due to Systemic Lupus Erythematosus Activation After Mitral Valve Plasty. Ann Thorac Surg 2017;104:e109–11. doi:10.1016/j.athoracsur.2017.01.073 | eng |
| dcterms.references | Kotkar KD, Said SM. Libman-Sacks Endocarditis in a Patient With Antiphospholipid Syndrome. Ann Thorac Surg 2016;102:e31–2. doi:10.1016/j.athoracsur.2015.11.004 | eng |
| dcterms.references | Chazal T, Kerneis M, Guedeney P, et al. Coronary artery disease in systemic lupus: A case-controlled angiographic study. Autoimmun Rev 2020;19:102427. doi:10.1016/j.autrev.2019.102427 | eng |
| dcterms.references | Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. J Autoimmun 2017;82:1–12. doi:10.1016/j.jaut.2017.05.008 | eng |
| dcterms.references | Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, et al. Cardiovascular Events in Systemic Lupus Erythematosus. Medicine (Baltimore) 2015;94:e1183. doi:10.1097/MD.0000000000001183 | eng |
| dcterms.references | Ke S-R, Liu C-W, Wu Y-W, et al. Systemic lupus erythematosus is associated with poor outcome after acute myocardial infarction. Nutr Metab Cardiovasc Dis 2019;29:1400–7. doi:10.1016/j.numecd.2019.08.006 | eng |
| dcterms.references | Fidler L, Keen KJ, Touma Z, et al. Impact of pulmonary disease on patientreported outcomes and patient-performed functional testing in systemic lupus erythematosus. Lupus 2016;25:1004–11. doi:10.1177/0961203316630818 | eng |
| dcterms.references | Moqin Z. Shrinking Lung Syndrome as the Initial Manifestation of SLE. Chest 2016;149:A474. doi:10.1016/j.chest.2016.02.493 | eng |
| dcterms.references | Buckley MM, Rabinovich CE. Pulmonary Manifestations of Rheumatic Diseases in Children. Pediatr Clin North Am 2021;68:147–66. doi:10.1016/j.pcl.2020.09.005 | eng |
| dcterms.references | Aguilera-Pickens G, Abud-Mendoza C. Pulmonary Manifestations in Systemic Lupus Erythematosus: Pleural Involvement, Acute Pneumonitis, Chronic Interstitial Lung Disease and Diffuse Alveolar Hemorrhage. Reumatol Clínica (English Ed 2018;14:294–300. doi:10.1016/j.reumae.2018.03.001 | eng |
| dcterms.references | Kokosi M, Lams B, Agarwal S. Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome. Clin Chest Med 2019;40:519–29. doi:10.1016/j.ccm.2019.06.001 | eng |
| dcterms.references | Goswami RP, Mondal S, Lahiri D, et al. Shrinking lung syndrome in systemic lupus erythematosus successfully treated with rituximab. QJM 2016;109:617– 8. doi:10.1093/qjmed/hcw093 | eng |
| dcterms.references | Duron L, Cohen-Aubart F, Diot E, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev 2016;15:994–1000. doi:10.1016/j.autrev.2016.07.021 | eng |
| dcterms.references | Chaudhury D, Qureshi A, Prasad S, et al. Catatonia – An unusual presenting clinical manifestation of systemic lupus erythematosus. Reumatol Clínica 2017;13:224–6. doi:10.1016/j.reuma.2016.03.013 | eng |
| dcterms.references | Hanly JG. Attribution in the assessment of nervous system disease in SLE. Rheumatology 2015;54:755–6. doi:10.1093/rheumatology/keu458 | eng |
| dcterms.references | Bortoluzzi A, Scirè CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology 2015;54:891–8. doi:10.1093/rheumatology/keu384 | eng |
| dcterms.references | Jafri K, Patterson SL, Lanata C. Central Nervous System Manifestations of Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2017;43:531–45. doi:10.1016/j.rdc.2017.06.003 | eng |
| dcterms.references | Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 2016;74:41–72. doi:10.1016/j.jaut.2016.06.013 | eng |
| dcterms.references | Hanly JG. Avoiding diagnostic pitfalls in neuropsychiatric lupus: the importance of attribution. Lupus 2017;26:497–503. doi:10.1177/0961203317690244 | eng |
| dcterms.references | Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014;10:338–47. doi:10.1038/nrrheum.2014.15 | eng |
| dcterms.references | Chaves WG, Carrero NE, Tejeda MJ. Linfadenopatías generalizadas como primera manifestación de lupus eritematoso sistémico; un diagnóstico diferencial de enfermedad linfoproliferativa. Un reporte de dos casos. Rev Colomb Reumatol 2015;22:225–30. doi:10.1016/j.rcreu.2015.08.005 | eng |
| dcterms.references | Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Published Online First: 2015. doi:10.1136/lupus-2014-000078 | eng |
| dcterms.references | Ournal THEJ, Ediatrics OFP. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. J Pediatr 2018;196:22-30.e2. doi:10.1016/j.jpeds.2018.01.045 | eng |
| dcterms.references | Fernanda M, Ávila R, María L, et al. Manifestaciones relacionadas con alteraciones en la coagulación en lupus eritematoso sistémico de inicio juvenil . Reporte de casos y revisión de la literatura. Rev Colomb Reumatol 2020;27:190–201. doi:10.1016/j.rcreu.2019.01.002 | spa |
| dcterms.references | Pueyo-Asensio C, Saint Gerons Trecu M, Rubio Pérez MA, et al. Holmes-Adie syndrome as an early manifestation of systemic lupus erythematosus. Arch la Soc Española Oftalmol (English Ed 2020;:11–4. doi:10.1016/j.oftale.2020.03.015 | eng |
| dcterms.references | Palejwala N V., Walia HS, Yeh S. Ocular Manifestations of Systemic Lupus Erythematosus: A Review of the Literature. Autoimmune Dis 2012;2012:1–9. doi:10.1155/2012/290898 | eng |
| dcterms.references | Knox Cartwright NE, Tole DM, Georgoudis P, et al. Peripheral Ulcerative Keratitis and Corneal Melt. Cornea 2014;33:27–31. doi:10.1097/ICO.0000000000000008 | eng |
| dcterms.references | Héron E, Gutzwiller-Fontaine M, Bourcier T. Sclérites et épisclérites : prise en charge diagnostique et thérapeutique. La Rev Médecine Interne 2014;35:577– 85. doi:10.1016/j.revmed.2014.02.004 | eng |
| dcterms.references | Md Noh UK, Zahidin AZA, Yong TK. Retinal vasculitis in systemic lupus erythematosus: an indication of active disease. Clin Pract 2012;2:54. doi:10.4081/cp.2012.e54 | eng |
| dcterms.references | Wu C, Dai R, Dong F, et al. Purtscher-like Retinopathy in Systemic Lupus Erythematosus. Am J Ophthalmol 2014;158:1335-1341.e1. doi:10.1016/j.ajo.2014.09.001 | eng |
| dcterms.references | Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol 2016;100:135–41. doi:10.1136/bjophthalmol- 2015-306629 | eng |
| dcterms.references | Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013;12:1085–90. doi:10.1016/j.autrev.2013.05.004 | eng |
| dcterms.references | Jara I. Puntos de encuentro entre la dermatología y la reumatología. Rev Chil Dermatol 2015;31:230–7. | spa |
| dcterms.references | Koo BS, Hong S, Kim YJ, et al. Lupus enteritis: clinical characteristics and predictive factors for recurrence. Lupus 2015;24:628–32. doi:10.1177/0961203314558858 | eng |
| dcterms.references | Brewer BN, Kamen DL. Gastrointestinal and Hepatic Disease in Systemic Lupus Erythematosus. Rheum Dis Clin North Am 2018;44:165–75. doi:10.1016/j.rdc.2017.09.011 | eng |
| dcterms.references | Zhang F, Zhang J, Zhou L, et al. Intestinal pseudo-obstruction as the initial manifestation of systemic lupus erythematosus. Am J Emerg Med 2019;37:176.e1-176.e2. doi:10.1016/j.ajem.2018.09.048 | eng |
| dcterms.references | Delgado N. Nefritis lúpica. Med infant 2000;7:272–8. | eng |
| dcterms.references | Ruiz-Irastorza G, Espinosa G, Frutos MA, et al. Diagnosis and treatment of Lupus nephritis: Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish society of internal medicine (SEMI) and the Spanish society of nephrology (S.E.N.). Nefrologia 2012;32:1–45. doi:10.3265/Nefrologia.pre2011.Dec.11298 | eng |
| dcterms.references | Mart GA, Gonz HJ. Nefritis lúpica. | spa |
| dcterms.references | Peñaranda P, Fernando L. Redalyc.Nefropatía lúpica. 2014. | spa |
| dcterms.references | Novillo Valdivieso MS, Ayala López IM, Mora Gonzalez MG, et al. Diagnóstico y tratamiento de la nefritis lúpica. Recimundo 2019;3:410–27. doi:10.26820/recimundo/3.(3).septiembre.2019.410-427 | spa |
| dcterms.references | Horta-Baas G, Camargo-Coronel A, Miranda-Hernández DG, et al. Renal Transplantation in Systemic Lupus Erythematosus: Comparison of Graft Survival With Other Causes of End-stage Renal Disease. Reumatol Clínica (English Ed 2019;15:140–5. doi:10.1016/j.reumae.2018.10.012 | eng |
| dcterms.references | Soliman WM, Sherif NM, Ghanima IM, et al. Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erythematosus: Relation With Disease Activity and Lupus Nephritis. Reumatol Clínica (English Ed 2020;16:255–61. doi:10.1016/j.reumae.2018.07.014 | eng |
| dcterms.references | Zurita Gavilanes L, Costa Valarezo A. Rituximab in Lupus Nephritis: A Nonsystematic Review. Reumatol Clínica (English Ed 2016;12:210–5. doi:10.1016/j.reumae.2016.01.001 | eng |
| dcterms.references | Morales E, Cánovas JM, Cavero T, et al. Afectación renal en las vasculitis, el lupus eritematoso y las enfermedades sistémicas. Med - Programa Form Médica Contin Acreditado 2015;11:4902–13. doi:10.1016/j.med.2015.06.012 | eng |
| dcterms.references | Miranda-Hernández D, Cruz-Reyes C, Angeles U, et al. Prognostic Factors for Treatment Response in Patients With Lupus Nephritis. Reumatol Clínica (English Ed 2014;10:164–9. doi:10.1016/j.reumae.2013.12.010 | eng |
| dcterms.references | Chowdhary VR. Broad Concepts in Management of Systemic Lupus Erythematosus. Mayo Clin Proc 2017;92:744–61. doi:10.1016/j.mayocp.2017.02.007 | eng |
| dcterms.references | Fulgeri C, Carpio JD, Ardiles L. Lesiones renales en el lupus eritematoso diseminado: ausencia de relación entre datos clínicos e histológicos. Nefrología 2018;38:386–93. doi:10.1016/j.nefro.2017.11.016 | spa |
| dcterms.references | Pinto Peñaranda LF, Castro Mercado IL, Duque Caballero V, et al. Predictive Risk Factors for Failure to Induction Therapy of Lupus Nephritis in a Cohort of Colombian Patients. Reumatol Clínica (English Ed 2014;10:147–51. doi:10.1016/j.reumae.2013.12.011 | eng |
| dcterms.references | Kalloo S, Aggarwal N, Mohan P, et al. Lupus Nephritis: Treatment of Resistant Disease. Clin J Am Soc Nephrol 2013;8:154–61. doi:10.2215/CJN.05870612 | eng |
| dcterms.references | Martín-Gómez MA, Rivera Hernández F, Frutos Sanz MÁ, et al. Recomendaciones y sugerencias a 4 preguntas clave en nefropatía lúpica: Extracto de la guía de práctica clínica 2015. Nefrología 2016;36:333–8. doi:10.1016/j.nefro.2016.01.013 | spa |
| dcterms.references | Guillén AVC, Rodríguez MLF. Protocol for diagnosis and treatment of lupus nephropathy. Med 2019;12:4849–52. doi:10.1016/j.med.2019.06.015 | eng |
| dcterms.references | Llanos L, Massardo L. Tratamientos Biológicos para Nefropa- tía Lúpica. 2015;31:11–4. | spa |
| dcterms.references | Curs G, Kumar P, Merino I, et al. Escola Universitària d ’ Infermeria Gimbernat. 2013;:1–97. | spa |
| dcterms.references | Mofetilo M, En MFM, Lúpica N. PROTOCOLO PARA EL USO DE Código : CRFT / PRO / MNL / FIA / 122015. 2015. | spa |
| dcterms.references | Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol 2020;16:167–78. doi:10.1038/s41584-020-0374-8 | eng |
| dcterms.references | García MP. clínicas fuera de ficha técnica . Experiencia en un hospital de tercer nivel . 2019;:1–36. | spa |
| dcterms.references | Han ES, goleman, daniel; boyatzis, Richard; Mckee A. 済無No Title No Title. J Chem Inf Model 2019;53:1689–99. | eng |
| dcterms.references | Fernández-García B, Martínez-Santana V, Ortega-Valín L, et al. Off-lable uses of mycophenolate mofetil: Lupus nephritis. Farm Hosp 2015;39:222–3. doi:10.7399/fh.2015.39.4.8135 | eng |
| dcterms.references | Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev 2018;17:1022–7. doi:10.1016/j.autrev.2018.04.007 | eng |
| dcterms.references | CICLOFOSFAMIDA VERSUS MICOFENOLATO EN NEFRITIS LÚPICA HOSPITAL NACIONAL HIPÓLITO UNANUE 2015-2019. 2020. | spa |
| dcterms.references | Batista SER, Grass AV, Del E, et al. Cyclophosphamide in the systemic sclerosis treatment. Correo Científico Médico de Holguín 2015;19:1–12. | eng |
| dcterms.references | Sehgal AR, Grey SF, DeOreo PB, et al. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997;30:41–9. doi:10.1016/S0272-6386(97)90563-1 | eng |
| dcterms.references | Pedraza OL, Salazar AM, Sierra FA, et al. Pedraza, Salazar, Sierra, Soler, Castro, Castillo, Hernández, Piñeros, 2016 VALIDACIÓN MoCA bogota. Acta Medica Colomb 2016;41:221–8. | spa |
| dcterms.references | Loureiro C, García C, Adana L, et al. Use of the montreal cognitive assessment (MoCA) in Latin America: A systematic review. Rev Neurol 2018;66:397–408. doi:10.33588/rn.6612.2017508 | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | eng |
| sb.programa | Especialización en Nefrología | spa |
| sb.sede | Sede Barranquilla | spa |